Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLIVAC FIX Birch dose-finding study in birch pollen allergic rhinitis
2011-004550-25Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Mar 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sublivac Birch in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (5 arms), sponsored by HAL Allergy Group. Primary endpoint: Change in TNPT total symptom score. Started Mar 2012; status: completed.
02
Drugs
Sublivac Birch
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2011-004550-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004550-25.